Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | EHMT2 | Q96KQ7 | 5/20 | 0.41 |
| ▸ | TOP2A | P11388 | 3/20 | 0.41 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.37 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15440528 | 0.94 | SMN1; SMN2 (0.45) | SMN1; SMN2NPC1MITFPOLBDNMT1 | |
| SCHEMBL15449640 | 0.91 | POLB (0.49) | SMN1; SMN2NPC1MITFPOLBDNMT1 | |
| SCHEMBL13468116 | 0.90 | SMN1; SMN2 (0.46) | SMN1; SMN2NPC1MITFPOLBDNMT1 | |
| SCHEMBL15440705 | 0.89 | POLB (0.57) | SMN1; SMN2NPC1MITFPOLBDNMT1 | |
| SCHEMBL15440679 | 0.89 | POLB (0.47) | SMN1; SMN2NPC1MITFPOLBDNMT1 | |
| SCHEMBL15440739 | 0.87 | RAB9A (0.50) | SMN1; SMN2NPC1MITFPOLBDNMT1 | |
| SCHEMBL15440706 | 0.86 | KMT2A (0.46) | SMN1; SMN2NPC1MITFPOLBDNMT1 | |
| SCHEMBL15440713 | 0.86 | EHMT2 (0.45) | SMN1; SMN2NPC1MITFPOLBDNMT1 | |
| SCHEMBL13281984 | 0.86 | SMN1; SMN2 (0.42) | SMN1; SMN2NPC1MITFPOLBDNMT1 | |
| SCHEMBL15440469 | 0.83 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1MITFPOLBDNMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9096536-B2 | Asymmetrically substituted anthrapyridazone derivatives as cytostatics | BS-154 S.P. ZO.O. (PL) | 2015-08-04 | — | — | US | claimed |
| US-20140031357-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | BS-154 SP. Z O.O. (PL) | 2014-01-30 | — | — | US | claimed |
| US-9096536-B2 | Asymmetrically substituted anthrapyridazone derivatives as cytostatics | BS-154 S.P. ZO.O. (PL) | 2015-08-04 | — | — | US | disclosed |
| US-20140031357-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | BS-154 SP. Z O.O. (PL) | 2014-01-30 | — | — | US | disclosed |
| WO-2012141604-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | INSTYTUT FARMACEUTYCZNY (PL) | 2012-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140031357-A1 | ASYMMETRICALLY SUBSTITUTED ANTHRAPYRIDAZONE DERIVATIVES AS CYTOSTATICS | ABCC1, ABCC3, ABCB1 | SMN1; SMN2 4813/4885NPC1 1872/4885MITF 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.